Patent JPS5497864A successfully refreshed from Google Patents.
US7763581B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Mutants of trichosanthin with anti-tumor activity and lowered side-effects
Assignee: Individual
•
Filing: 2005-08-04
•
Granted: 2010-07-27
•
Expires: 2025-08-04
Abstract
Abstract The invention provides the mutants and coding genes of trichosanthin (TCS). The mutants thereof are the TCS mutants with the single or double alternation of tyrosine-55 and aspartate-78 (counted from N-terminus), wherein the tyrosine-55 is mutated to an aliphatic amino acid and aspartate-78 is mutated to an amino acid with low hydrophilicity. This invention also relates to the application of TCS mutants and their coding genes in the drug development to treat carcinoma, AIDS and other diseases.
Inventors
- 👤 Chengcai An
- 👤 Shuangli Mi
- 👤 Ye Wang
- 👤 Yin Gao
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 23:33
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/415; A; A61; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P35/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
59 words
A mutant of trichosanthin, wherein at least one of the tyrosine-55 and aspartate-78 (counted from the N-terminus of trichosanthin of SEQ ID NO. 8) are mutated, with the tyrosine-55 being mutated to an aliphatic amino acid selected from the group consisting of alanine, valine, leucine, and isoleucine, and the aspartate-78 being mutated to an amino acid with low hydrophilicity.
Claim 2
Dependent Claim
59 words
A mutant of trichosanthin, wherein at least one of the tyrosine-55 and aspartate-78 (counted from the N-terminus of trichosanthin of SEQ ID NO. 8) are mutated, with the tyrosine-55 being mutated to an aliphatic amino acid selected from the group consisting of alanine, valine, leucine, and isoleucine, and the aspartate-78 being mutated to an amino acid with low hydrophilicity.
Claim 3
Dependent Claim
27 words
The mutant of claim 1 , wherein the tyrosine-55 (counted from the N-terminus of trichosanthin of SEQ ID NO. 8) is mutated to an aliphatic amino acid.
Claim 4
Dependent Claim
24 words
The mutant of claim 1 , wherein the aspartate-78 (counted from the N-terminus of TCS) is mutated to an amino acid with low hydrophilicity.
Claim 5
Dependent Claim
50 words
The mutant of claim 1 , wherein the tyrosine-55 (counted from the N-terminus of trichosanthin of SEQ ID NO. 8) is mutated to an aliphatic amino acid, and the aspartate-78 (counted from the N-terminus of trichosanthin of SEQ ID NO. 8) is mutated to an amino acid with low hydrophilicity.
Claim 6
Dependent Claim
23 words
The mutant as claimed in claim 4 , wherein the amino acids with low hydrophilicity is serine, threonine, asparagine, glutamine, alanine, or cysteine.
Claim 7
Dependent Claim
29 words
A method of treating a subject having a carcinoma comprising administering to the subject a medicament comprising the trichosanthin of SEQ ID NO. 8 mutant of claim 1 .
References Cited (Backward Citations)
WO1990012097A1
Cited
WO2002012537A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2013-07-26 | 2014-01-25 | 2014-07-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2017-07-26 | 2018-01-25 | 2018-07-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2021-07-26 | 2022-01-25 | 2022-07-27 | $7700.00 | Window Closed / Lapsed |